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Abstract 
 
CD8
+
 T cells represent a sizable component of the liver inflammatory infiltrate in chronic 
hepatitis C and are thought to contribute to immune-mediated tissue injury. Since chronic 
stimulation may promote the expression by CD8
+
 T cells of distinct human leukocyte antigen 
(HLA) Class I specific, Natural Killer cells receptors (NKRs) susceptible to both inhibit 
effector functions and promote cell survival, we examined the distribution and characteristics 
of CD8
+
 T cells with such receptors in chronic hepatitis C patients. NKRs CD8
+
 T cells were 
detectable in liver and peripheral blood from HCV-infected patients but were not major 
subsets. However, the frequency of NKG2A
+
CD8
+  
in liver and in a lesser extent in peripheral 
blood was positively correlated to histological activity in HCV-infected patients.  No such 
correlation was found with KIR
+
 T cells in liver in  HCV-infected patients and with the both 
NKR CD8+ T cells  in hepatitis B virus (HBV)- infected patients. Circulating CD8
+
 T cells 
expressing killer cell immunoglobulin-like receptors (KIRs) exhibited phenotypic features of 
memory T cells but with exacerbated expression of the senescence marker CD57 in patients. 
NKG2A
+
CD8
+
 T cells were committed T cells that appeared less differentiated than 
KIRs
+
CD8
+
 T cells. In HCV-infected patients their content in perforin was low and similar to 
that observed in NKG2A
-
CD8
+
 T cells, a scenario not observed in healthy subjects and HBV-
infected patients. Both NKG2A and KIRs could inhibit HCV-specific CD8
+
 T cells response 
ex vivo. In conclusion, these results support the concept that accumulation in liver 
parenchyma of NKR
+
CD8
+
 T cells that have functional alterations could be responsible for 
liver lesions. They provide novel insights into the complexity of liver infiltrating CD8
+
 T cells 
in chronic hepatitis C and reveal that distinct subsets of antigen-experienced CD8
+
 T cells are 
differentially sensitive to the pervasive influence of HCV  
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Introduction 
Hepatitis C is a liver-targeting infectious disease caused by a non cytopathic RNA 
virus (HCV). If HCV is not rapidly cleared by the immune system, the infection becomes 
chronic, causes inflammation, mononuclear cell infiltration, hepatocytes destruction, 
progression to fibrosis, can lead to cirrhosis and in some instance, to hepatocellular carcinoma 
(1, 2). While vigorous HCV specific T cell responses can allow for virus clearance, HCV 
persists in a majority of cases (3-6). Among liver lymphocytes of chronic hepatitis C (cHC) 
patients are many activated CD8
+
 T cells (7). Such a population comprises very few T cells 
reactive to HCV because HCV-specific CD8
+
 T cells are difficult to detect within the 
persistently infected liver (8-10). HCV-specific CD8
+
 T cells differ from other virus-specific 
CD8
+
 T cells by their incomplete differentiation status. For instance, many of them retain 
expression of CD27 and CD28 costimulatory molecules that are missing on fully 
differentiated cytomegalovirus (CMV)-specific CD8
+
 T cells (11). Our knowledge of CD8
+
 T 
cells in cHC has thus progressed. Nevertheless, some features remain poorly explored. In 
particular, some Natural Killer cells receptors (NKRs) that bind human leukocyte antigen 
class I (HLA-I) can be expressed by CD8
+
 T cells and greatly influence their properties. 
Although the expression of some NKRs has been examined in some chronic viral infections, 
including Epstein-Barr virus (EBV), CMV and human immunodeficiency virus (HIV) 
infections (12-15) less is known with respect to NKRs expression by CD8
+
 T cells in cHC.  
Depending on the nature of the ligand binding domain, HLA-I reactive NKRs can be 
subdivided in two major groups. The first group corresponds to molecules whose ectodomain 
belongs to the C-type lectin domain family such as NKG2A that associates with CD94 to 
form inhibitory heterodimers. The second group corresponds to molecules whose ectodomain 
consists of immunoglobulin (Ig)-like domains. It includes KIRs (killer cell Ig-like receptors) 
such as CD158 molecules, and LIR1/ILT2 (leukocyte Ig-like receptor 1/Ig-like transcript 2). 
While CD94:NKG2 heterodimers react to the non classical HLA-I molecule HLA-E, KIR 
family members bind to polymorphic residues of classical HLA-I molecules. As to 
LIR1/ILT2, it reacts to a monomorphic portion of classical HLA-I with poor affinity and with 
marginal functional consequences  relative to KIRs or NKG2A (16-20).  
KIRs are absent on naïve CD8
+
 T lymphocytes but they can be surface expressed on 
CD8
+
 T cells harboring memory cell-associated phenotypic features. In most cases, they 
correspond to KIRs with high affinity for their HLA-I ligands and that can negatively regulate 
effector functions (inhibitory KIRs) (19). KIRs expression by CD8
+
 T cells, reflecting prior 
TCR engagement, is stable and remains unaltered in culture (21, 22). With respect to the 
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inhibitory heterodimer CD94:NKG2A, its surface expression on CD8
+
 T cells depends on 
TCR engagement and is observed on T cells with memory/effector phenotype (23). Various 
observations support the notion that HLA-I reactive inhibitory NKRs expressed by CD8
+
 T 
cells can impair their effector functions (13, 14, 24-26). In addition, KIRs and NKG2A 
expression can impact on CD8
+
 T cell persistence via modulation of their susceptibility to 
activation-induced cell death (AICD) and possibly, promote their accumulation (19).  
In cHC patients, initiation and progression of liver damages, which are characterized 
by portal lymphoid infiltration and degenerative lobular lesions, are essentially driven by the 
host immune response (3). CD8
+
 T cells are abundant within the diseased liver, both in the 
lobular and periportal areas (7, 27) and can be cytotoxic for HCV-infected as well as non-
infected liver cells through various mechanisms (9, 28, 29). Given these characteristics and 
because HLA-I specific NKRs can be expressed by committed CD8
+
 T cells, NKRs
+
CD8
+
 T 
cells could contribute to the progression toward chronicity both by impairing the function of 
HCV specific CD8
+
 T cells and by promoting the accumulation of activated CD8
+
 T cells at 
large within the liver. We therefore examined the expression of NKG2A (Z199 antibody) as 
well as of CD158a/h and CD158b/j KIRs members (EB6 and GL183 antibodies) by 
intrahepatic and circulating CD8
bright
 T lymphocytes from patients with characterized HCV 
chronic infection compared to healthy controls and HBV-infected patients. 
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Patients and Methods 
Patients.  
Thirty four chronic HCV-infected patients seen in our clinical department for a liver biopsy 
from January to December 2005 were included in the study (Table 1). Each patient had 
serologic markers of HCV infection and presence of serum HCV RNA. Criteria for exclusion 
were age under 18 years, presence of serum HbsAg or anti-HIV antibodies, other causes of 
chronic liver disease, alcohol consumption higher than 30 g/day, and current or past 
immunomodulatory or antiviral treatment. Serum alanine aminotransferase (ALT) levels were 
determined at the time of the liver biopsy and were expressed as multiple of the upper limit of 
the normal. Anti-HCV antibodies were tested by third-generation ELISA (Ortho Diagnostic 
Systems, Raritan, NJ). Serum HCV-RNA titer was measured by RT-Q-PCR (Monitor 2.0 
HCV, Roche Diagnostic Systems, Meylan, France) at the time of the liver biopsy. HCV 
genotype was determined by direct sequencing (Trugene HCV 5’NC; Visible Genetics Inc., 
Toronto, Canada). Patients underwent percutaneous liver biopsy (16-gauge hepafix needle) as 
part of their diagnostic evaluation. Blood samples from patients were collected at the same 
time of the biopsy in heparinized vacutainer tubes. Peripheral blood mononuclear cells 
(PBMCs) were isolated by using Ficoll-hypaque density gradient separation. Two control 
groups were studied for PBMCs experiments : 13 chronically mono HBV-infected patients 
seen in the same clinical department, and 22 healthy volunteers obtained from our blood bank 
(Etablissement Français du Sang, La Tronche, France).  The study was in agreement with the 
local ethics committee recommendations and all patients gave a written informed consent.  
 
Liver samples and Immunohistological analysis. 
Liver biopsies were processed for histopathological examination by a single independent 
pathologist (NS) using the METAVIR scoring system. Each biopsy was cut in five micro 
meters thick cryostat sections, dried and fixed in formol. Immunostaining was performed 
using an indirect streptavidin biotin peroxydase method with an anti-CD8 antibody (C8/144B 
clone, Dako). For cell suspension analysis, fresh fragments collected in RPMI 1640 10 % of 
rhesus AB human serum were washed extensively to minimize blood cells contamination and 
disrupted mechanically into small pieces in complete media. Cell suspensions were prepared 
in complete media by using a glass mortar. Cells were washed and processed immediately for 
immunoanalysis.  
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Bulk expansion of intrahepatic lymphocytes. 
Infiltrating T lymphocytes were isolated from fresh liver tissue and expanded as we described 
elsewhere (30). Briefly, cells were expanded polyclonally (unprimed, bulk-expanded) in the 
presence of irradiated (30 Gy) autologous PBMCs (10
5
 cells/well), recombinant 
interleukin(IL)-2 (100 IU/ml) and phytohemaglutinin A (PHA) (2 g/ml) in 96 well plates 
(10
5
 cells/well) for 2 weeks in RPMI 1640 media containing 10% AB human serum, 1 mM 
glutamine, 1% non-essential amino acids, 1% sodium pyruvate, 50 g/ml 
penicillin/streptomycin (Gibco Life Sciences, Rockville, MD) at 37°C in 5% CO2 atmosphere. 
Half of the media was replaced twice a week and cells were splitted at confluence. Expanding 
cells were maintained for 2-3 weeks without restimulation with addition of media and IL-2. 
Bulk-expanded lymphocytes were used directly or cryopreserved. 
 
Antibodies and multimers 
The antibodies used were anti-HLA-A2-Fluorescein Isothiocyanate (FITC) (clone BB7.2), 
anti-CD3-R-Phycoerythrin-Cyanine 5 (PE)Cy5 (UCHT1), anti-CD8-FITC (SK1), anti-
CD28-FITC (CD28.2), anti-CD27-FITC (M-T271), anti-CD45RA-FITC (HI100), anti-
CD45RO-FITC (UCHL1), anti-CD57-FITC (NK-1), anti-CD85j/LIR1-PE /FITC (GHI/75) 
and anti-Perforin-FITC (G9) from Becton-Dickinson Biosciences (Le Pont-de-Claix, 
France). Anti-CD8-Allophycocyanin (APC) (B9.11), anti-CD158a,h purified or PE/APC-
coupled (EB6), anti-CD158b1,b2,j purified or PE/APC-coupled (GL183), anti-
NKG2A/CD159A purified or PE-coupled (Z199), anti-CD94-PE (HP3B1) were obtained 
from Beckman Coulter France (Villepinte, France). Anti-NKG2A-APC (131411) and purified 
anti-CD158b2/KIR2DL3 (180701) was from R&D Systems (Lille, France). Anti-CD62L-
FITC (FMC46) was from Serotec (Oxford, UK). F(ab')2 of goat anti-mouse (GAM) IgG-FITC 
was from Jackson ImmunoResearch (West Grove, PA). Soluble R-PE-labeled HCV 
peptide:HLA-A*0201 multimers containing the non-structural (NS)31073-1081, NS31406-1415 and 
NS52594-2602 peptides were obtained from Proimmune Limited (Oxford, UK). Staining was 
performed according to the manufacturer instructions. 
 
Immunostaining and Flow Cytometry. 
Fresh PBMCs/intrahepatic samples (0.2 to 1 x 106 cells) were incubated with a saturating 
amount of appropriate labeled antibodies in phosphate-buffered saline (PBS) (30 min, 4°C). 
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Cells were washed twice and
 
analyzed immediately. For indirect staining, cells first were
 
incubated with unconjugated primary mAb, followed
 
by a F(ab')2 fragment of goat GAM-
FITC. For intracellular staining, cells were first surface stained, washed and subjected to 
fixation/permeabilisation (Cytofix/Cytoperm kit, BD PharMingen), prior to intracellular 
staining according to the manufacturer instructions. Multi-parameter flow cytometric analysis 
was performed on a FACSCalibur instrument with the CellQuest software (Becton Dickinson, 
Mountain View, CA). Nonviable cells
 
were excluded by electronic gating or propidium 
iodide. Depending on the conditions, 20.000 to 200.000 gated events were acquired.  
 
Functional assay. 
For stimulation assay of T cells from HLA-A*0201
+
 patients, cells used were total PBMCs or 
unprimed, bulk-expanded, iHLs plus autologous, T-depleted PBMCs. Cells were cultured for 
16-18hrs with a mixture of HCV peptides (3 g/ml) that bind to HLA-A2 in the presence of 
anti-KIRs (EB6 + GL183), anti-NKG2A (Z199) or an isotype-matched (IgG1), irrelevant 
antibodies (5 g/ml). Cultures were set up in duplicates in a final volume of 200 l of 
complete media. The peptides used were : Core35-44, 90-98, 131-140, 156-165 et 177-185 et 
NS31073-1081, 1131-1139, 1169-1177, 1284-1298, 1406-1415, 1443-1451 et 1585-1593. 
Supernatants were harvested for detection of TNF- by ELISA (OptEIA ELISA kit, BD 
Biosciences). 
 
Statistical analysis 
Comparisons between group of patients and controls were performed using the nonparametric 
Mann-Whitney U-test and Kruskall-Wallis tests. Within-group comparisons were evaluated 
using the Wilcoxon signed rank’s test. Bivariate correlations were done by computing a 
Spearman’s correlation coefficient. All comparisons were 2-tailed. When multiple 
comparisons were done on a given experiment the p value was corrected by multiplying by 
the number of comparisons. P values less than 0.05 were considered significant. The 
statistical analysis was conducted using the SPSS 9.0 software (SPSS Inc., Chicago, IL). 
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Results 
 
CD8
bright
 T lymphocytes enrichment in damaged liver from cHC patients. 
We previously observed a positive correlation between liver lesions severity and the 
frequency of intrahepatic CD3
+
 lymphocytes in cHC patients (30). We also found an 
accumulation of CD8 transcripts in liver biopsies with high histological activity index 
relative to samples with milder index (31). We therefore examined here the frequency of 
CD3
+
CD8
bright
 lymphocytes (thereafter referred to as CD8
+
 T cells) in liver biopsies from cHC 
patients presenting with various degrees of histological lesions. The flow cytometry analysis 
showed that an elevated fraction of CD3
+
CD8
+
 intrahepatic lymphocytes was associated with 
a more pronounced histological activity (p < 0.04) (Fig. 1). This observation was corroborated 
by an in situ analysis by immunostaining showing a large number of CD8
+
 T cells 
surrounding areas of lobular and periportal necrosis (Fig. 2). The latter result is in line with a 
recent immunochemistry study that has shown a higher CD8
+
 T cell infiltrate in liver from 
patients with Metavir activity superior to 1 compared to those who had mild activity (32). 
Taken together, these results strongly support the concept that in cHC patients, the 
progression from mild to marked histological lesions is associated with an increase in the size 
of the liver CD8
+
 T cell pool.  
 
Ex vivo detection of CD8
+
 T cells expressing HLA-I specific NKRs  
Because NKRs
+
CD8
+
 T cells are antigen-experienced cells whose presence might be 
associated to chronic stimulation (12, 33), we investigated whether substantial fractions of 
intrahepatic CD8
+
 T cells from cHC patients could express CD158a/h and CD158b/j KIR as 
well as NKG2A and CD94 receptors. The data in Fig. 3 indicate that both PBMCs and IHL 
from cHC patients do comprise CD8
+
 T cells with surface expression of NKG2A, CD94 or 
CD158a/h-CD158b/j KIR molecules. These populations were not major subsets among 
intrahepatic T cells, with frequencies in liver ranging on average from 4% for CD158a to 12% 
for CD94 (Table 2). Interestingly, the percentage of NKRs
+
CD8
+
 T visualized in liver was 
significantly correlated to that observed in blood. The strongest correlations were observed for 
NKG2A (r=0.72,p<0.006) and CD94 (r=0.82, p<0.001) (Fig. 4). For each NKR
+
CD8
+
 T cell 
subset there was a trend toward an enrichment in liver compared to blood that was significant 
only for CD158b (11 vs 4%, p<0.01). Finally, we compared circulating NKRs
+
CD8
+
 T cells 
frequencies observed in cHC patients to both cHB patients and healthy controls and we  
observed no significant differences between the three groups (Table 2).  
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Increased liver injury correlates with high frequency of NKG2A
+
CD8
+
 T lymphocytes. 
Since KIRs and NKG2A expression by CD8
+
 T cells reflect prior TCR-mediated activation in 
vivo (19, 33), we searched for possible correlation between the frequency of NKRs
+
CD8
+
 T 
cells and disease severity. We found a significant correlation between histological activity and 
frequency of intrahepatic NKG2A
+
CD8
+
 T cells (r = 0.645, p<0.02), and in a lesser extent 
with circulating peripheral NKG2A
+
CD8
+
 T cells (r=0.41, p<0.05). By contrast, the frequency 
of liver CD94
+
CD8
+
 T cells seemed to negatively correlate with lesion severity but this trend 
failed to reach statistical significance (r = -0.543, p = 0.055).  No correlation was found with 
the fibrosis stage. Correlations between the frequency of KIR
+
CD8
+
 T cells and biochemical 
and virological characteristics were not significant. The correlation between circulating 
NKG2A
+
CD8
+
 T cells and histological activity was not observed in the cHB group (r=0.04, 
p=0.82). Thus, the salient feature of this analysis is that in cHC, but not in cHB, patients, an 
increase percentage of NKG2A
+
CD8
+
 T cells subset is associated to an enhanced histological 
activity. 
 
NKG2A or KIRs expression by intrahepatic HCV-specific CD8
+
 T cells in cHC patients. 
To determine whether NKR expression could be detected among HCV-specific liver CD8
+
 T 
cells, we performed costaining with HCV-peptide/HLA-class I multimers reagents. Although 
the frequency of CD8
+
 T cells specific for a given peptide/HLA-A2 complex may be higher in 
the liver than in the blood (34, 35), it usually remains very low. For this reason, we used a 
cocktail of three multimer reagents made of HLA-A*0201 molecules complexed to the 
NS31073-1081, NS31406-1415 and NS52594-2602 HCV epitopes. Fig. 5A shows that it is possible to 
detect very low fractions of HCV-specific CD8
+
 T cells expressing NKG2A or KIRs receptors 
among unprimed, bulk-expanded, intrahepatic lymphocytes. Both NKG2A
+
 and KIRs
+
 HCV-
specific CD8
+
 T cell frequencies were lower than that of HCV-specific cells expressing 
LIR1/ILT2 molecules. We included the LIR1/ILT2 control since in other infectious diseases 
these molecules can be expressed by higher fractions of virus-specific CD8
+
 T cells than KIRs 
(19). Although a limited number of epitopes were studied here, the data indicate that liver 
CD8
+
 T cells from cHC patients can comprise fractions of NKRs
+
 virus-specific cells. Since 
KIRs expression is a feature of antigen-experienced, terminally differentiated, CD8
+
 T cells 
(12), the data indicates that some HCV specific CD8
+
 T cells, albeit at low frequency, do 
undergo extensive differentiation during cHC.  
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NKG2A and KIRs modulate the reactivity of HCV-specific CD8
+
 T cells from cHC 
patients. 
To determine whether NKG2A and KIRs expression is susceptible to impact on the reactivity 
of HCV specific CD8
+
 T cells, we stimulated PBMCs from HLA-A2
+
 patients with various 
HCV peptides, that bind to HLA-A2, in the presence or absence of anti- NKG2A or -KIRs 
Abs and measured TNF- secretion in the supernatant. We observed that neutralizing KIRs 
engagement, and in a minor extend NKG2A engagement, did enhance the response of virus-
specific CD8
+
 T cells to specific stimulation in vitro (Fig. 5B). Similar results were obtained 
when unprimed, bulk-expanded, intrahepatic lymphocytes were used in the assay. Thus, 
NKRs expressed by HCV-specific CD8
+
 T cells from patients are functional and are capable 
of interfering with their specific response in vitro.  
 
Phenotypic features of NKRs
+
CD8
+
 T cells  
To study the differentiation status of NKRs
+
CD8
+
 T cells, we examined their phenotype. Due 
to the limited CD8
+
 T cell number that can be recovered from biopsies, we used PBMCs 
(Table III). In all groups, most KIRs(CD158a/h plus CD158b/j)
+
CD8
+
 T cells expressed 
CD45RA and only few expressed CD45RO. Concerning the replicative senescence marker 
CD57, we observed that, while the frequency of positive cells was comparable between 
KIRs
+
CD8
+
 T cells from patients and controls, there was a marked increase in the CD57 
expression level on CD57
+
KIRs
+
CD8
+
 T cells from cHC patients as revealed by the mean 
fluorescence intensity (MFI)(Fig. 6A, B). This effect was not observed in the case of cHB 
patients. KIR
+
CD8
+
 T cells from all cohorts comprised a minority of cells positive for CD27 
and CD28 relative to their KIR
-
 counterparts with however, a trend toward a further reduced 
CD28
+
 cell frequency in HCV
+
 patients (Fig. 6C), that was also detected for cHB patients. 
With respect to NKG2A
+
CD8
+
 T cells, the high proportions of CD45RO
+
, CD27
+
 and CD28
+
 
cells seen in controls were virtually unchanged in cHC patients. As to CD57, the proportion of 
positive cells among NKG2A
+
CD8
+
 T cells was lower than among KIR
+
CD8
+
 T cells and 
there was no change in expression level (not shown). Overall, the analysis of CD8
+
 T cells 
expressing either KIRs or NKG2A indicates that both subsets display characteristics of 
effector/memory CD8
+
 T cells. NKG2A
+
CD8
+
 T cells appeared less differentiated than 
KIRs
+
CD8
+
 T cells. Finally, the phenotype of distinct NKRs
+
CD8
+
 subsets can show subtle 
distinctions between cHC patients and controls.  
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Scarcity of perforin
+
 cells among blood NKG2A
+
CD8
+
 T cells from cHC patients. 
Because perforin is central to granule exocytosis-dependent cytotoxicity, the lytic potential of 
NKRs
+
CD8
+
 T cells was estimated by studying the perforin cellular content. Intracellular 
stainings in controls showed that blood KIRs
+
CD8
+
 and NKG2A
+
CD8
+
 T cells were both 
enriched in perforin
+
 cells relative to NKR
-
CD8
+
 T cells (Fig. 7A). However, while this 
enrichment was fairly stable among KIRs
+
CD8
+
 T cells, the proportion of perforin
+
 cells 
among NKG2A
+
CD8
+
 T lymphocytes was reduced in cHC patients (Fig. 7B). This difference 
is reminiscent of the reduced frequency of perforin
+
CD8
+
 T cells previously noticed in HCV
+
 
patients (36) and was not noticed in the case of HBV
+
 patients (Fig. 7B). Thus, during cHC, it 
might exist a differential modulation of perforin expression among subsets of CD8
+
 T cells 
expressing distinct NKRs. 
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Discussion 
Conventional CD8
+
 T lymphocytes are largely suspected to be involved in the 
pathogenesis of chronic hepatitis C (7, 27, 30-32, 37, 38). The first finding of our study 
supports this concept by unraveling a significant correlation between frequencies of intra-
hepatic CD8
bright
 T cells and histological activity and by showing in situ CD8+ 
immunostainings in close contact to lobular and periportal hepatocyte necrosis. It has been 
reported in various pathologies that KIRs and NKG2A receptors could be expressed on 
antigen-experienced CD8
+
 T cells under conditions of chronic stimulation/inflammation and 
impact on their functions and/or persistence (12, 33). We have then examined CD8
bright
 T cells 
expressing these markers in liver and blood of cHC patients in terms of frequencies, 
functionalities and association to liver pathogenesis. While there was no overt accumulation 
of KIRs
+
CD8
+
 or NKG2A
+
CD8
+
 T cells in patients, our results indicate that within the liver, 
the frequency of NKG2A
+
CD8
+
, but not KIRs
+
CD8
+
 T cells correlates with lesion severity. 
Possibly, the increased frequency of NKG2A
+
CD8
+
 T cells we found in liver samples with 
marked lesion severity could relate to the fact that the liver can retain committed CD8
+
 T cells 
(39-41), a phenomenon that could be reinforced during chronic inflammation. In theory, liver 
NKG2A
+
CD8
+
 T cells could contribute to lesions because some of them were perforin
+
 and 
there were blasting cells with a high forward light scatter (not shown). In addition, the 
inhibitory effect of NKG2A is not necessarily as efficient as that triggered by inhibitory KIRs 
at interfering with CD8
+
 T cell lytic activity (19, 20, 25, 42). We have indeed shown that 
KIRs, rather than NKG2A, were effectively capable of modulating the reactivity of specific 
anti-HCV CD8
+
 T cells. It is worth to note, the scarcity of HCV specific CD8
+
 T cells we 
observed in liver is consistent with the estimated frequency of intra-hepatic CTLs usually 
reported (8-10). Therefore, the substantial deleterious role for liver of HCV reactive 
NKG2A
+
CD8
+
 T cells may result not only from their direct action, but would rely also on 
bystander phenomena. On the other hand, liver NKG2A
+
CD8
+
 T cells could be neutralized 
because NKG2A can, in some systems, efficiently control CD8
+
 T cell functions (26, 43). It is 
known that such an inhibition greatly depends on HLA-E availability (19, 20) and in the case 
of hepatitis C, liver HLA-E expression appears enhanced (44) making NKG2A
+
CD8
+
 liver T 
cells very likely to have their cytotoxic potential constrained in situ. In addition, since 
repeated TCR engagements is necessary for high NKG2A expression (45), and because the 
interaction with HLA-E does not modulate NKG2A expression (46), our observation that 
NKG2A MFI was slightly lower on liver NKG2A
+
CD8
+
 T cells from patients than on their 
circulating counterparts (not shown) suggests that intrahepatic NKG2A
+
CD8
+
 T cells are not 
Bonorino et al 
NKRs+ CD8 T cells in chronic Hepatitis C  Page 13 of 28 
overtly reactive in situ. Finally, an elevated HLA-E expression is likely to provide 
NKG2A
+
CD8
+
 liver T cells with anti-apoptotic signals since CD94 expression is high on 
NKG2A
+
CD8
+
 T cells (47-48) and high CD94 expression associates with an enhanced 
resistance to cell death (49). Thus, the increased frequency of NKG2A
+
CD8
+
 T cells in 
biopsies with marked lesions could reflect a selective survival advantage. It is possible that 
this association indeed reflects a combination of several factors including the retention of 
activated/memory CD8
+
 T cells, an HLA-E-mediated resistance to cell death and perhaps, 
some level of activation/expansion. Albeit technically difficult, further experiments are hence 
needed to fully understand the properties of liver NKG2A
+
CD8
+
 T cells during cHC. With 
respect to blood cells, we detected the increased frequency of NKG2A
+
CD8
+
 T cells reported 
by Nattermann et al.(50) in some (nearly 20%), but not all, cHC patients. The reasons for this 
difference could relate to genetic factors, risk factors, and/or to differences in the virus 
genotype as well as in duration of infection. Taken together, the decrease of cytotoxic 
functions of NKG2A+ CD8+ T at single cell level could be compensated by increase survival 
favoring a long lasting accumulation of this population which eventually induces hepatocyte 
lesions. 
Phenotypically, KIRs
+
CD8
+
 T cells from patients were committed cells with a 
memory-like phenotype resembling that of terminal effector cytotoxic CD8
+
 T cells (19). 
NKG2A
+
CD8
+
 T cells were also antigen-experienced cells since there were enriched in 
CD45RO
+
 cells but they were less differentiated than KIRs
+
CD8
+
 T cells because many were 
CD27
+
CD28
+
 cells. TCR engagement is required for NKG2A surface expression by activated 
CD8
+
 T cells during infection (23). Therefore, NKG2A
+
CD8
+
 T cells from patients must have 
responded to TCR-mediated stimulations in vivo. Given that the frequency of 
NKG2A
+
CD8
+
perforin
+
 T cells seemed reduced in patients, the data suggest that the 
differentiation of NKG2A
+
CD8
+
 T cells might be altered in persistent HCV infection. While 
the fractions of NKG2A
+
CD8
+
 and KIRs
+
CD8
+
 T cells that expressed CD57 were quite 
comparable between patients and controls, the CD57 expression was enhanced on KIRs
+
CD8
+
 
T cells from HCV but not HBV patients. Since CD57 expression by CD8
+
 T cells reflects a 
history of intense mitosis and a status of proliferative inability (51), we conclude that the 
majority KIRs
+
CD8
+
 T cells from cHC patients are truly terminally differentiated cells that 
have undergone more extensive in vivo division than their counterparts from controls. 
Through yet unknown mechanism(s), HCV infection can influence the phenotype of 
antigen-specific CD8
+
 T cells. Thus, CMV-specific CD8
+
 T cells from HCV
+
 patients are less 
differentiated than their counterparts from controls. This phenomenon is referred to as 
Bonorino et al 
NKRs+ CD8 T cells in chronic Hepatitis C  Page 14 of 28 
pervasive influence (36). In this line, we found phenotypic distinctions between NKRs
+
CD8
+
 
T cells from cHC patients and both healthy individuals and cHB patients. For example, most 
KIRs
+
CD8
+
 T cells from cHC patients showed signs of enhanced replicative senescence, and 
perforin
+
 cells tended to be less frequent among NKG2A
+
CD8
+
 T cells. This suggests 
therefore that HCV pervasive influence can affect various subsets of committed CD8
+
 T cells 
and that distinct such subsets can be differentially susceptible to this influence.  
In summary, CD8
+
 T lymphocytes that express either KIRs or NKG2A are T cell 
subsets which have undergone TCR-mediated activation in vivo in cHC patients. Their 
expression on HCV-specific CD8
+
 T cells is rare but associated, especially for KIRs, to a 
clear impairment of HCV-specific reactivity. Within the inflamed liver, CD8
+
 T cells 
expressing KIRs or NKG2A are variable among patients in terms of frequencies and display 
phenotypic and functional alterations which are not observed in controls or cHB patients. We 
hypothesize these changes are the consequence of the known pervasive influence of HCV that 
differentially affects CD8
+
 subsets. Finally, NKG2A
+
 CD8
+
 T cells, whose functional 
impairment seems to be compensated by a survival advantage favoring accumulation in liver, 
appear to be a major player in HCV pathogenesis.      
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Figures and Legends. 
 
Figure 1. Increased frequency of CD8
+
 T lymphocytes in more severely injured liver 
during chronic Hepatitis C. 
Significant association between the fraction of intrahepatic CD3
+
CD8
bright
 assessed flow 
cytometry and METAVIR activity (A1: mild; A2 : moderate, A3 severe) (p < 0.03, n = 17). 
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Figure 2 Immunohistology of CD8 expressing cells in liver of chronic viral hepatitis C 
patients. 
The distribution of CD8 expressing cells in liver biopsies from patients, with low activity 
(A1) in panel A and B, and high activity (A3) in panel C and D, is detected by staining with 
anti-CD8 antibody. Few CD8 positive cells are present in fibrous septa (S) and portal tracts 
(PT), some of them in contact with rare foci of parcellar necrosis (arrow). Numerous CD8 
positive T lymphocytes are seen in fibrous septa and portal tracts and also in lobules, in close 
contact with foci of lobular necrosis (asterisk) and in large areas of parcellar necrosis. 
Magnification is x 10 for panel A and C, and x 20 for panel B and D. 
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Figure 3. Presence of CD8
+
 T cells with surface expression of HLA class I specific NKRs 
in peripheral blood and liver tissue from cHC  patients. 
The surface expression of CD158a/h, CD158b/j, NKG2A and CD94 was examined on 
peripheral blood cells (PBMCs) (A) and on intrahepatic lymphocytes (iHLs) (B) in patients 
with chronic hepatitis C by using four-color immunostaining as outlined in Methods. 
Representative flow cytometry data were plotted after electronic gating on CD3
+
CD8
bright
 
lymphocytes (R2 in top panels). y axis: cell count. 
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Figure 4 : Correlation between frequencies of NKG2A+ (A) and CD94+ (B) CD8+ T 
cells in PBMCs and liver 
Frequencies (expressed as percentage) assessed in 16 patients whose IHL and PBMCs 
collected at the same time were available. Results are significant for NKG2A 
(r=0.72,p<0.006) and CD94 (r=0.82, p<0.001). 
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Figure 5. Expression of functional KIRs and NKG2A receptors by HCV-specific CD8
+
 T 
cells from HLA-A*0201
+
 cHC patients. 
(A) HCV-specific CD8
+
 T cells present among bulk-expanded, iHLs were examined for 
expression of KIRs or NKG2A. KIRs (CD158a,h,b,j) and NKG2A expression were plotted 
after a combination of electronic gating defining CD3
+
CD8
+
 T cells and HCV peptide:HLA-
A*0201 Multimer
+
 cells. The peptides bound to  HLA-A*0201 were NS31073-1081, NS31406-1415 
and NS52594-2602. The data are from four independent experiments where HCV-specific cells 
were detected among expanded iHLs.  
(B) Modulation of HCV-specific CD8
+
 T cell reactivity by KIRs and NKG2A. PBMCs or 
bulk-expanded, iHLs were stimulated with multiple HCV peptides that bind to HLA-A2 (see 
methods) in the presence of anti-KIRs Abs (EB6 + GL183), anti-NKG2A Ab (Z199) or 
isotype-matched control (Is.C., IgG1) Ab (5 g/ml). Supernatants were harvested prior to 
detection of TNF- by ELISA. The data are representative of three independent experiments. 
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Figure 6. Phenotypic traits of KIRs
+
CD8
+
 T cells in chronically HCV-infected patients. 
(A) Representative profiles for CD57 expression by KIRs
-
 and KIRs
+
CD8
+
 blood T cells from 
a control and a cHC patient. The fraction of CD57
+
 cells is shown for both KIRs
-
 and KIRs
+
 
cells after gating on CD3
+
CD8
+
 cells. The mean fluorescence intensity (MFI) is indicated. 
The antibodies used comprised a mixture of anti-CD158a,h and anti-CD158b,j mAbs. (B) The 
expression level of CD57 was increased in cHC patients (n = 5) relative to both controls (n = 
4) (p = 0.014) and HBV
+
 patients (n = 13) (p = 0.001). The data correspond to the ratio of 
CD57 MFI KIRs
+
CD8
+
 T cell to CD57 MFI KIRs
-
CD8
+
 T cells. (C) The frequency of blood 
KIR
+
CD8
+
 T cells expressing CD28 tended to be decreased in cHC patients (n = 7) relative to 
controls (n = 5) (p = 0.061) and was decreased in HVB
+
 patients (n = 13) (p = 0.012). The 
KIR antibodies used comprised a mix of anti-CD158a,h and anti-CD158b,j mAbs. 
  
(A)      KIRs
-
CD8
+
 T cells          KIRs
+
CD8
+
 T cells  
 
 
 
 
Control 
 
 
 
 
 
 
 
 
cHC Patient 
 
 
 
 
 
                    CD57 Log fluorescence intensity 
  
             (B)                   *p 0.05              *p 0.05                               (C)                               *p 0.05  
                                           
                      
   
 
 
 
 
 
 
 
 
 
 
15% 
MFI= 2049 
11% 
MFI= 1311 
40% 
MFI= 1877 
                                           43% 
                                MFI= 3476 
0
10
20
30
40
50
60
70
%
C
D
2
8
+
/K
IR
+
 C
D
8
+
 T
 c
e
ll
s
c
o
n
tr
o
ls
p
a
ti
e
n
ts
 c
H
C
p
a
ti
e
n
ts
 H
B
V
+
p = 0.06 
Bonorino et al 
NKRs+ CD8 T cells in chronic Hepatitis C  Page 25 of 28 
Figure 7. The perforin content of blood CD8
+
 T cells with surface expression of NKRs in 
cHC patients.  
 (A) Representative profiles for perforin content of NKRs
-
CD8
+
 versus NKRs
+
CD8
+
 
circulating T cell populations for a control and a cHC patient. The fraction of perforin positive 
cells is indicated for both NKRs
-
 and NKRs
+
 cells after gating on CD3
+
CD8
bright
 lymphocytes. 
The perforin content was examined by intracellular immunostaining as outlined in Methods. 
A mixture of anti-CD158a,h and anti-CD158b,j mAbs was used to assess KIRs surface 
expression. (B) The proportion of perforin positive cells among NKG2A
+
CD8
+
 T cells tended 
to be reduced in cHC patients (n = 5) relative to controls (n = 5) (p = 0.06) and cHB (n=13) 
(p=0.11). 
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___________________________________________________________________________ 
Table 1: Demographic and clinical characteristics of patients included in the study. 
___________________________________________________________________________ 
HCV
+
 (n = 34)   HBV
+
 (n = 13) 
 
Female Sex*     15 (30 %)   7 (53,8 %) 
 
Age (years)**     46 (28 - 75)   39 (21 - 58) 
 
Source of infection*       
Intravenous drug abuse    13 (38 %)   0  
Transfusion     10 (29 %)   0 
Materno-foetal           0    3 (23%) 
Other modes       4 (12 %)   5 (38%) 
Unknown       7 (21 %)   5 (38%) 
 
 
Duration of infection (years)**   21 (2-42)         - 
 
Plasma Viral load (log IU/ml) **  6.10 (4.47 - 6.95)        3,75 (2,37 – 6,91) 
 
Viral genotype*          
1a      4 (12%) 
1b      13 (38 %) 
2        5  (15 %) 
3        7  (14 %) 
4        4  (12 %) 
ND        2  (6 %)    
 
ALT (IU/ml)**     57 (22 - 226)             45 (20 - 132) 
 
Liver Histology* 
Metavir activity score       
1      16 (47 %)   6 (46%) 
2      13 (38 %)   5 (38%) 
3        5  (15%)   2 (15%) 
 
Metavir fibrosis score       
0        2   (6 %)   2 (15%) 
1      13 (38 %)   5 (38%) 
2      10 (29 %)   3 (23%) 
3        3   (9 %)   2 (15%) 
4        5   (15 %)   1 (8%) 
___________________________________________________________________________ 
 
* Number of cases/total (percentage %) 
** Median (range) 
IU/ml : international units par milliliter 
ALT : alanine aminotransferase 
Note that for technical reasons (number of cells available per sample), the entire set of experiments described 
could not be performed for every single patients.  
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___________________________________________________________________________ 
Table 2: Frequencies of NKRs
+
CD8
+
 T cells in liver and blood 
___________________________________________________________________________ 
 
CD158a
+
 CD158b
+
 NKG2A
+
 CD94
+
 
___________________________________________________________________________ 
 
HCV IHLs (n=17)  4 (1-9)  10 (2-28) 5 (1-14) 12 (1-69)  
 
HCV Blood (n=28)  2 (1-18) 4 (1-18) 4 (1-21) 10 (1-78) 
 
HBV Blood (n=13)  2 (1-20) 3 (1-16) 4 (2-21) 5 (2-21) 
 
Controls (n=22)  2 (1-40) 4 (1-26) 3 (1-70) 7 (1-72) 
___________________________________________________________________________ 
 
 
 
Results expressed as percentages (median and ranges) 
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_________________________________________________________________________ 
TABLE 3: Phenotypic features of peripheral blood CD8
+
 T cells subsets expressing 
HLA-class I specific NK receptors during chronic Hepatitis C. 
_________________________________________________________________________ 
 
 
              with in  C D 3+C D 8+K IR+               with in  C D 3+C D 8+N K G 2A +               within CD3+CD8+LIR-
C on trols Patien ts cHC C on trols Patien ts cHC
% C D 45RA + 85 76 52 67
(65-97) (59-97) (32-75) (26-99)
% C D 45RA
high
68 58 30 25
(58-92) (45-92) (18-37) (18-91)
% C D 45RO + 23 11 81 76
(2 -28) (7 -50) (71-83) (27-90)
% C D 27+ 52 28 86 84
(19-69) (5-66) (75-91) (8-97)
% C D 28+ 21 9 74 75
(8 -62) (4 -33) (52-88) (23-91)
% C D 62L+ 56 19 36 16
(7 -75) (7 -45) (23-65) (7-45)
% C D 62L
high
24 12 22 4
(3 -56) (2 -25) (5-37) (2-10)
% C D 57+ 64 56 28 29
(38-62) (35-95) (11-52) (15-86)   
 
              with in  C D 3+C D 8+K IR-               with in  C D 3+C D 8+N K G 2A -               within CD3+CD8+LIR-
C on trols Patien ts cHC C on trols Patien ts cHC
% C D 45RA + 72 55 76 68
(47-85) (42-68) (47-84) (55-92)
% C D 45RA
high
64 46 68 59
(36-71) (23-57) (37-72) (37-83)
% C D 45RO + 21 44 28 37
(16-34) (37-53) (16-31) (15-48)
% C D 27+ 90 81 92 79
(72-96) (37-92) (69-97) (42-94)
% C D 28+ 79 71 86 79
(52-96) (57-79) (58-93) (37-91)
% C D 62L+ 40 32 61 31
(26- 73) (27-41) (41-77) (10-40)
% C D 62L
high
11 11 51 9
(6 -58) (7 -24) (8-62) (2-27)
% C D 57+ 18 16 22 25
(4 -20) (5 -56) (6-25) (8-49)  
The values  represent the percentage (median (range)) of positive
 
cells among CD8
bright
  
T cells expressing or lacking KIRs or NKG2A receptors. Differences in frequency 
were not statistically significant. 
 
